Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Quadriplex model enhances urine-based detection of prostate cancer
Ist Teil von
Prostate cancer and prostatic diseases, 2011-12, Vol.14 (4), p.354-360
Ort / Verlag
London: Nature Publishing Group UK
Erscheinungsjahr
2011
Quelle
MEDLINE
Beschreibungen/Notizen
Background:
The major advantages of urine-based assays are their non-invasive character and ability to monitor prostate cancer (CaP) with heterogeneous foci. While the test for the prostate cancer antigen 3 (
PCA3
) is commercially available, the aim of our research was to test other putative urine markers in multiplex settings (
AMACR
(α-methylacyl-CoA racemase),
EZH2
(enhancer of zeste homolog 2),
GOLM1
(golgi membrane protein 1),
MSMB
(microseminoprotein, β),
SPINK1
(serine peptidase inhibitor) and
TRPM8
(transient receptor potential cation channel, subfamily M, member 8)).
Methods:
Expression of the candidate biomarkers was studied in sedimented urine using quantitative reverse transcriptase polymerase chain reaction in two sets of patients with and without restriction on serum PSA levels.
Results:
We confirmed that
PCA3
is an independent predictor of cancer in the patients without restriction of serum PSA values (set 1,
n
=176, PSA=0.1–587 ng ml
–1
). However,
AMACR
was the only parameter that differentiated CaP from non-CaP patients with serum PSA between 3 and 15 ng ml
–1
(set 2,
n
=104). The area under curve (AUC) for this gene was 0.645 with both sensitivity and specificity at 65%. Further improvement was achieved by multivariate logistic regression analysis, which identified novel duplex (
TRPM8
and
MSMB
), triplex (plus
AMACR
) and quadriplex (plus
PCA3
) models for the detection of early CaPs (AUC=0.665, 0.726 and 0.741, respectively).
Conclusions:
Novel quadriplex test could be implemented as an adjunct to serum PSA or urine
PCA3
and this could improve decision making for diagnostics in the case of ‘PSA dilemma’ patients.